

4TH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT LISTING SHEET**Information Cited By Applicant(s) That May Be Material To
The Prosecution Of The Subject Application**

Applicants: George et al. Attorney Docket No. BIOL0119
 Serial No.: 10/593,018 Group Art Unit:
 Filed: October 22, 2008 Examiner:

Confirmation No. 5725

Title: IMAGE BASED QUANTITATION OF MOLECULAR TRANSLOCATION

U.S. PATENT DOCUMENTS

*Examiner Initial	ID	Document No.	Date	Inventor Name(s)	Class	Sub- Class
_____	US1	4,959,302	9/25/1990	Cornaby et al.	435	5
_____	US2	5,939,281	8/17/1999	Lehmann et al.	435	7.94
_____	US3	5,965,366	10/12/1999	Ochoa et al.	435	6
_____	US4	6,150,121	11/21/2000	Hamawy et al.	435	7.24
_____	US5	7,306,921	12/11/2007	Nevalainen et al.	435	7.1
_____	US6	7,476,514	1/13/2009	Britz et al.	435	7.24
_____	US7	2007/0122806	5/31/2007	Strom et al.	435	6
_____	US8	2009/0088409	4/2/2009	Charlton	514	171

FOREIGN PATENT DOCUMENTS

NONE CITED

OTHER INFORMATION

*Examiner Initial	Document No.	Document Information
_____	O1	Colombo et al., "Biopsy coupled to quantitative immunofluorescence: a new method to study the human vascular endothelium." <i>Journal of Applied Physiology</i> , Vol. 92: 1331-1338, 2002.
_____	O2	Giese et al., "Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective towards individually optimized drug doses of cyclosporine A." <i>Transplantation</i> , Vol. 77, No. 3: 339-344, 2004.

OTHER INFORMATION

<u>*Examiner</u> <u>Initial</u>	<u>Document</u> <u>No.</u>	<u>Document Information</u>
_____	O3	Hartel et al., "Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: a quantitative measure of the efficacy of cyclosporine A-based immunosuppression." <i>Clinical Chemistry</i> : 10 pp., 2002.
_____	O4	Manna et al., "Immunosuppressive Leflunomide Metabolite (A77 1726) Blocks TNF-Dependent Nuclear Factor- κ B Activation and Gene Expression." <i>The Journal of Immunology</i> , Vol. 162: 2095-2102, 1999.
_____	O5	Wong et al., "Prognostic and Diagnostic Significance of Beta-Catenin Nuclear Immunostaining in Colorectal Cancer." <i>Clinical Cancer Research</i> , Vol. 10: 1401-1408, 2004.

Examiner's Signature

Date

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Documents cited herein marked with an "*" have not previously been cited in a priority application relied upon herein for an earlier filing date. Copies of any so-noted Foreign Patent Documents and Other Information are enclosed for the Examiner's use.

MCKaelm
1/31/11